| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/06/2005 | US20050002909 Methods and compositions for treating intervertebral disc degeneration |
| 01/06/2005 | US20050002888 Water-in-silicone emulsions |
| 01/06/2005 | US20050002878 Use of tazarotene for preparing a nail varnish for treating and/or preventing psoriasis and nail varnish containing same |
| 01/06/2005 | US20050002873 Injectable foam; controlling blood dispersion of gases; cardiovascular disorders |
| 01/06/2005 | US20050002870 Spray drying; needleless injection |
| 01/06/2005 | US20050002869 Metered dose inhaler having internal surfaces coated with fluorocarbon polymer |
| 01/06/2005 | US20050002867 Buccal, polar and non-polar sprays containing propofol |
| 01/06/2005 | US20050002860 Compositions comprising a tissue glue and therapeutic agents |
| 01/06/2005 | US20050000390 Low-viscosity opacifiers free from anionic surface-active agents |
| 01/06/2005 | US20050000388 Aqueous emulsification in presence of ammonium hydroxide; regulating electrolyte content using ion exchange resin or membrane |
| 01/06/2005 | CA2723328A1 Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs |
| 01/06/2005 | CA2530385A1 Melt extruded controlled release oxycodone multiparticulates |
| 01/06/2005 | CA2530328A1 Production of capsule shells and capsules |
| 01/06/2005 | CA2530120A1 Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof |
| 01/06/2005 | CA2530113A1 Bioerodible sustained release drug delivery systems |
| 01/06/2005 | CA2529456A1 Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs |
| 01/06/2005 | CA2529447A1 Tablet comprising fluvastatin and carmellose calcium |
| 01/06/2005 | CA2526150A1 Treatment of humans with colloidal silver composition |
| 01/06/2005 | CA2525928A1 A method of treating degenerative disc disease |
| 01/06/2005 | CA2524937A1 Transmucosal form of administration with reduced mucosal irritation |
| 01/06/2005 | CA2494707A1 Pharmaceutical solid dosage forms exhibiting reproductible drug release profile |
| 01/05/2005 | EP1493444A1 Pharmaceutical composition used as anti-infective of the upper respiratory tract |
| 01/05/2005 | EP1493436A1 Compositions for parenteral administration and sustained-release of therapeutic agents |
| 01/05/2005 | EP1493435A1 Controlled Release Compositions of Betahistine |
| 01/05/2005 | EP1493434A1 Extended release acetaminophen |
| 01/05/2005 | EP1493433A1 Porous particles loaded with cosmetical or pharmaceutical active agents |
| 01/05/2005 | EP1492909A1 Polymeric fibre and method for making same |
| 01/05/2005 | EP1492821A1 Iron dextrin compounds for the treatment of iron deficiency anaemia |
| 01/05/2005 | EP1492816A2 Modulators of the notch signalling pathway and uses thereof in medical treatment |
| 01/05/2005 | EP1492776A2 Iodinated triglyceride analogs |
| 01/05/2005 | EP1492774A2 Pyrimidone derivatives useful for the treatment of inflammation and immunological diseases |
| 01/05/2005 | EP1492577A1 Film-forming compositions for protecting skin from body fluids and articles made therefrom |
| 01/05/2005 | EP1492569A1 Aqueous dispersible steryl ester compositions |
| 01/05/2005 | EP1492566A2 Binding agents and their use in targeting tumor cells |
| 01/05/2005 | EP1492557A2 Xcrf polynucleotides and polypeptides and uses thereof |
| 01/05/2005 | EP1492554A2 Spherical protein particles and methods of making and using them |
| 01/05/2005 | EP1492551A2 Ophthalmic, pharmaceutical and other healthcare preparations with naturally occuring plant compounds, extracts and derivatives |
| 01/05/2005 | EP1492538A1 Meloxicam suppositories containing e.g. polyethylenglycol |
| 01/05/2005 | EP1492532A1 Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations |
| 01/05/2005 | EP1492531A2 Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin |
| 01/05/2005 | EP1492529A1 Oral administration of epothilones |
| 01/05/2005 | EP1492527A2 Process for preparing a finely self-emulsifiable pharmaceutical composition |
| 01/05/2005 | EP1492522A1 Ansamycin formulations and methods for producing and using same |
| 01/05/2005 | EP1492520A1 Pharmaceutical compositions |
| 01/05/2005 | EP1492517A2 Hot melt tts for administering rotigotine |
| 01/05/2005 | EP1492514A1 A method for treating carrier particles and its use |
| 01/05/2005 | EP1492513A1 Hfa-suspension formulations containing an anticholinergic |
| 01/05/2005 | EP1492512A1 Method for systemic drug delivery through the nail |
| 01/05/2005 | EP1492511A2 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
| 01/05/2005 | EP1492510A1 Low dose liquid entecavir formulations and use |
| 01/05/2005 | EP1492509A1 Dosage form providing time-varying patterns of drug delivery |
| 01/05/2005 | EP1492508A1 Controlled release dosage forms |
| 01/05/2005 | EP1492507A2 Clarithromycin formulations having improved bioavailability |
| 01/05/2005 | EP1492506A2 Matrix for sustained, invariant and independent release of active compounds |
| 01/05/2005 | EP1492505A2 Pharmaceutical preparation containing oxycodone and naloxone |
| 01/05/2005 | EP1492504A2 Taste masked compositions of erythromycin a and derivatives thereof |
| 01/05/2005 | EP1492503A1 Stabilized natural cannabinoid formulation |
| 01/05/2005 | EP1492502A1 Novel polymorphs and pseudopolymorphs of risedronate sodium |
| 01/05/2005 | EP1492501A1 Methods of using lamellar bodies for therapeutic purposes |
| 01/05/2005 | EP1492500A1 Formoterol and ciclesonide aerosol formulations |
| 01/05/2005 | EP1492499A1 Formoterol and mometasone aerosol formulations |
| 01/05/2005 | EP1492498A2 Hfa-suspension formulation of an anhydrate |
| 01/05/2005 | EP1492438A2 Device and method to maintain vascularization near implant |
| 01/05/2005 | EP1492417A1 Encapsulated agglomeration of microcapsules and method for the preparation thereof |
| 01/05/2005 | EP1441602A4 Molecular press dehydration method for vegetative tissue using the solid phase of water soluble polymer substances as a dehydrating agent |
| 01/05/2005 | EP1429791A4 Method and topical formulation for treating skin conditions associated with aging |
| 01/05/2005 | EP1420643A4 Enhancement of transfection of dna into the liver |
| 01/05/2005 | EP1318792B1 Sustained release composition containing clarithromycin |
| 01/05/2005 | EP1255532B1 Osmotically-driven fluid dispenser |
| 01/05/2005 | EP1248630B9 Use of a dermatological composition containing oligosaccharides for the treatment of skin diseases |
| 01/05/2005 | EP1239837B1 Direct compression polymer tablet core |
| 01/05/2005 | EP1171134A4 Controlled release of sildenafil delivered by sublingual or buccal administration |
| 01/05/2005 | EP1150648A4 Use of water-soluble/dispersible reactive derivatives of polyimido compounds for modifying proteinaceous substrates |
| 01/05/2005 | EP1133300B1 Desmethylolanzapine compositions and methods |
| 01/05/2005 | EP1109537B1 Immediate release oral formulation comprising peptide thrombin inhibitors and a combination of microcrystalline cellulose and sodium starch glycollate |
| 01/05/2005 | EP1073413B1 Methods and compositions for stabilizing acetylcholine compositions |
| 01/05/2005 | EP1032371B1 Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances |
| 01/05/2005 | EP1003488B1 Method for preparing vesicular nanocapsules |
| 01/05/2005 | EP0881891B1 Male contraceptive implant |
| 01/05/2005 | DE202004015931U1 Omega-3-Fettsäuren und Omega-6-Fettsäuren enthaltende Zusammensetzung Omega-3 fatty acids and omega-6 fatty acids containing composition |
| 01/05/2005 | DE10327674A1 Injizierbare Darreichungsform von Flupirtin Injectable dosage form of flupirtine |
| 01/05/2005 | DE10325989A1 Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung A process for preparing and resulting micropellets and their use |
| 01/05/2005 | DE10297329T5 Dexibuprofen enthaltende Weichgelatinekapseln und Verfahren zu ihrer Herstellung Dexibuprofen-containing soft gelatin capsules and methods for their preparation |
| 01/05/2005 | CN2668119Y Hard capsule filled with heterotablet in it |
| 01/05/2005 | CN1561393A Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| 01/05/2005 | CN1561387A Probiotic bifidobacterium strains |
| 01/05/2005 | CN1561343A Soluble T cell receptor |
| 01/05/2005 | CN1561341A Hydrolysis of [R(R*, R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| 01/05/2005 | CN1561233A Sanitary napkins with hydrophobic lotions |
| 01/05/2005 | CN1561230A Antigenic compositions |
| 01/05/2005 | CN1561221A Novel medicinal herbal composition for treating liver diseases and HIV |
| 01/05/2005 | CN1561214A New formulations and use thereof |
| 01/05/2005 | CN1561213A New formulations and use thereof |
| 01/05/2005 | CN1561210A Preparation of selective epoxide hydrolase II inhibitor |
| 01/05/2005 | CN1561209A Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| 01/05/2005 | CN1561203A Pharmaceutical salts |
| 01/05/2005 | CN1561202A Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same |
| 01/05/2005 | CN1561201A Pharmaceutical compositions comprising colloidal silicon dioxide |
| 01/05/2005 | CN1561200A Flashmelt oral dosage formulation |
| 01/05/2005 | CN1561199A Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |